BLB&B Advisors LLC Has $362000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Lloyd Doyle
February 24, 2018

Over the last quarter, insiders sold 432,768 shares of company stock valued at $33,919,138. The institutional investor held 7,400 shares of the building materials company at the end of 2017Q3, valued at $2.65 million, up from 6,300 at the end of the previous reported quarter. North Tide Capital Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $105.69B market cap company. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company's stock worth $147,000 after purchasing an additional 1,613 shares during the last quarter. About 5.63 million shares traded.

Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Gilead Sciences, Inc. It has underperformed by 38.50% the S&P500. The company has market cap of $799.29 million. They expect $1.59 EPS, down 27.73% or $0.61 from last year's $2.2 per share. About 19.61M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 24, 2017 and is downtrending. It has underperformed by 10.32% the S&P500.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need.

Analysts await The KEYW Holding Corporation (NASDAQ:KEYW) to report earnings on March, 14. During the same period previous year, the business earned $2.70 EPS. GILD's profit will be $2.08 billion for 12.72 P/E if the $1.59 EPS becomes a reality. Fil Limited stated it has 0.48% in Gilead Sciences, Inc.

Catalyst Capital Advisors Llc, which manages about $653.50M and $2.29 billion US Long portfolio, decreased its stake in Stanley Black & Decker Inc (NYSE:SWK) by 9,640 shares to 2,580 shares, valued at $390,000 in 2017Q3, according to the filing. Finally, BMO Capital Markets upped their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a "market perform" rating in a research report on Thursday, February 8th. Therefore 70% are positive. The firm has "Buy" rating by Seaport Global given on Thursday, January 21. The firm has "Hold" rating by Goldman Sachs given on Wednesday, January 3. The firm has "Buy" rating by KeyBanc Capital Markets given on Friday, September 1. (NYSE:ANTM) has "Hold" rating given on Friday, August 18 by Jefferies. The firm has "Buy" rating by Cowen & Co given on Tuesday, May 30. On Tuesday, July 25 the stock rating was maintained by Mizuho with "Buy". As per Thursday, February 11, the company rating was initiated by Oppenheimer. The company was maintained on Wednesday, July 29 by Oppenheimer. (NASDAQ:GILD) for 360,893 shares. J.P. Morgan maintained Gilead Sciences, Inc.

Since August 30, 2017, it had 0 insider purchases, and 15 selling transactions for $56.94 million activity. (NASDAQ:GILD) shares. MARTIN JOHN C sold $6.05M worth of stock or 73,333 shares. Has $18.35 Million Position in Gilead Sciences, Inc. Washington Robin L sold $4.40 million worth of Gilead Sciences, Inc.


Investors sentiment increased to 1.03 in Q3 2017. Its up 0.25, from 1.1 in 2017Q2.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Moreover, Pinnacle Wealth Advisory Group Limited has 0.25% invested in Gilead Sciences, Inc. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. (NASDAQ:GILD). Valueworks Ltd accumulated 71,908 shares. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the company a buy rating in a report on Wednesday, October 25th. Wealthtrust Axiom Ltd Liability Corp invested 0.61% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 310,069 shares. 241,661 are held by Madison Investment Incorporated. Nichols And Pratt Advisers Llp Ma holds 0.03% in The Sherwin-Williams Company (NYSE:SHW) or 900 shares. Holowesko Ltd has 1.22 million shares for 7.86% of their portfolio. Vetr raised Gilead Sciences from a "buy" rating to a "strong-buy" rating and set a $91.25 price objective for the company in a research report on Monday, February 5th. Auxier Asset Management grew its stake in shares of Gilead Sciences by 1.4% in the 2nd quarter. The At Bancorp holds 4,307 shares with $349,000 value, down from 34,811 last quarter. Following the sale, the chairman now directly owns 3,046,766 shares of the company's stock, valued at approximately $254,587,766.96. (NASDAQ:GILD) has "Hold" rating given on Monday, August 28 by Maxim Group. (NYSE:ANTM) to report earnings on April, 25. The firm has "Buy" rating by UBS given on Friday, October 16. BMO Capital Markets maintained it with "Hold" rating and $7200 target in Friday, July 21 report. The company was downgraded on Wednesday, September 27 by Raymond James.

Investors sentiment increased to 1.14 in Q3 2017. Its up 0.19, from 0.78 in 2017Q2. It fall, as 60 investors sold SHW shares while 210 reduced holdings. Camarda Financial Advisors Llc, a Florida-based fund reported 39,499 shares. Corporate insiders own 1.30% of the company's stock. Somerville Kurt F holds 0.49% or 30,117 shares in its portfolio. Avalon holds 0.82% or 316,312 shares. Augustine Asset Mgmt owns 51,158 shares for 2.65% of their portfolio. Invesco Limited invested in 280,524 shares. Credit Suisse Ag reported 708,881 shares. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company's stock valued at $452,000 after buying an additional 100 shares during the period. 15,734 are held by Profund Advsrs Ltd Com. Paloma stated it has 0.01% of its portfolio in Sanchez Energy Corporation (NYSE:SN). The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.67 by $0.11. Aperio Gp Ltd Liability Corporation accumulated 0.41% or 905,862 shares.

Carret Asset Management Llc increased its stake in Citigroup Inc (C) by 19.43% based on its latest 2017Q3 regulatory filing with the SEC. It also reduced its holding in Medtronic Plc (NYSE:MDT) by 4,040 shares in the quarter, leaving it with 24,116 shares, and cut its stake in Pfizer Inc (NYSE:PFE).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER